SCHEMBL23345455

SCHEMBL23345455

Cc1ccc(Nc2nc(N/N=C/c3c[nH]c4ccccc34)nc(N3CCSCC3)n2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.81
▸ KMT2A Q03164 8/20 0.81
▸ MEN1 O00255 7/20 0.81
▸ LMNA P02545 5/20 0.81
▸ NPSR1 Q6W5P4 3/20 0.81
▸ THRB P10828 1/20 0.81
▸ GAA P10253 5/20 0.69
▸ CYP1A2 P05177 1/20 0.69
▸ CYP3A4 P08684 1/20 0.69
▸ CYP2C9 P11712 1/20 0.69
▸ CYP2C19 P33261 1/20 0.69
▸ PIKFYVE Q9Y2I7 1/20 0.69
▸ L3MBTL1 Q9Y468 2/20 0.63
▸ POLB P06746 1/20 0.63
▸ ALDH1A1 P00352 1/20 0.56
▸ SENP7 Q9BQF6 6/20 0.56
▸ SENP8 Q96LD8 4/20 0.56
▸ SENP6 Q9GZR1 4/20 0.56
▸ CASP3 P42574 2/20 0.56
▸ CA12 O43570 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23345501 0.92 MAPT (0.85) MAPTKMT2AMEN1LMNANPSR1
SCHEMBL23345480 0.92 MAPT (0.85) MAPTKMT2AMEN1LMNANPSR1
SCHEMBL23345484 0.91 MAPT (0.84) MAPTKMT2AMEN1LMNANPSR1
SCHEMBL23345495 0.90 MAPT (0.82) MAPTKMT2AMEN1LMNANPSR1
SCHEMBL23345460 0.90 KMT2A (0.82) MAPTKMT2AMEN1LMNANPSR1
SCHEMBL23326605 0.90 MAPT (1.00) MAPTKMT2AMEN1LMNANPSR1
SCHEMBL23326606 0.90 MAPT (1.00) MAPTKMT2AMEN1LMNANPSR1
SCHEMBL23345457 0.90 MAPT (1.00) MAPTKMT2AMEN1LMNANPSR1
SCHEMBL23345510 0.89 MAPT (0.80) MAPTKMT2AMEN1LMNANPSR1
SCHEMBL23345502 0.87 MAPT (0.77) MAPTKMT2AMEN1LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030896-B2 PIKfyve inhibitors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2024-07-09 — — US disclosed
US-20240016810-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS YUMANITY THERAPEUTICS, INC. 2024-01-18 — — US disclosed
US-20210139505-A1 PIKfyve Inhibitors Sanford Burnham Prebys Medical Discovery Institute 2021-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030896-B2 PIKfyve inhibitors PIKFYVE, PIP4K2B, PIP4K2A MAPT 3914/4885KMT2A 1410/4885MEN1 1445/4885
US-20210139505-A1 PIKfyve Inhibitors PIKFYVE, PIP4K2B, PIP4K2A MAPT 3914/4885KMT2A 1410/4885MEN1 1445/4885
US-20240016810-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS TARDBP, PIKFYVE, FUS MAPT 33/4885KMT2A 1078/4885MEN1 4321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback